Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Koral
Pgi21 - Cost-Effectiveness Analysis of Ustekinumab Versus Adalimumab, Infliximab and Vedolizumab for the Treatment of Patients With Moderately to Severe Active Crohn’s Disease for Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Minimization Analysis of Infliximab Versus Adalimumab in the Treatment of Crohn’s Disease and Ulcerative Colitis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?
Digestive Diseases and Sciences
Physiology
Gastroenterology
Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Pgi22 - Cost-Effectiveness of Vedolizumab Versus Ustekinumab in United Kingdom Crohn's Disease Patients Who Previously Failed TNF Inhibitor Therapy
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Adalimumab for Endoscopic and Histopathological Mucosal Healing in Paediatric Patients With Moderate to Severe Crohn’s Disease
Przeglad Gastroenterologiczny
Gastroenterology
Psy114 - Cost-Effectiveness of Vedolizumab Compared With Conventional Therapy in Patients With Crohn’s Disease in the United Kingdom (Uk)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Utility Analysis of Infliximab and Adalimumab for Refractory Ulcerative Colitis
Cost Effectiveness and Resource Allocation
Health Policy
Subtherapeutic Concentrations of Infliximab and Adalimumab Are Associated With Increased Disease Activity in Crohn’s Disease
Therapeutic Advances in Gastroenterology
Gastroenterology
